New insider activity at Sight Sciences ( (SGHT) ) has taken place on January 21, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sight Sciences has seen a wave of insider selling across its top leadership team. Chief Legal Officer Jeremy B. Hayden sold 6,308 shares of Sight Sciences stock for proceeds of $41,758. President & CEO Paul Badawi executed the largest transaction, selling 22,362 shares for a total of $148,036. Chief Technology Officer David Badawi sold 4,836 shares valued at $32,014, while Chief Financial Officer James Rodberg sold 2,616 shares for $17,317. These coordinated sales highlight significant share disposals by multiple senior executives at the company.
Recent Updates on SGHT stock
Over the last day, Sight Sciences’ shares have been influenced by a series of bullish analyst actions and company updates tied to improving fundamentals. Management highlighted about 7% year-over-year Q4 revenue growth, strong cash management, progress toward cash flow breakeven without new equity, and—critically—key Dry Eye milestones, including Medicare fee schedules and early validation of its reimbursed interventional Dry Eye business model. Analysts cited growing confidence in the TearCare opportunity, while still noting the need for additional payer coverage, and better‑than‑expected performance in the surgical glaucoma business with a more optimistic outlook into FY26. Another firm raised its valuation view as prior challenges facing the company appear to be diminishing. These factors together underpinned the recent upward revisions to expectations and supported the stock’s positive risk‑reward profile and recent outperformance.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
The score is held back primarily by weak financial performance: steep TTM revenue decline, sizable losses, and ongoing cash burn. Technical signals also remain bearish (negative MACD and price below key short-term averages). Offsetting these, the latest earnings call included improved guidance, better expense outlook, and positive reimbursement progress for TearCare, providing some support despite continued losses.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
YTD Price Performance: -21.31%
Average Trading Volume: 257,109
Technical Sentiment Signal: Buy
Current Market Cap: $342.1M